Husam A. Ghanim PhD

Husam Ghanim

Husam A. Ghanim
PhD

Contact Information
875 Ellicott Street
Buffalo, New York 14203
Phone: 716-881-8924
Fax: 716-639-1200
ghanim@buffalo.edu



Professional Summary:

My research has been focused on conducted basic and clinical research for over last 20 years. My lab is mainly Interested in understanding molecular mechanisms of insulin resistance, diabetes, obesity and weight loss focusing on the role of inflammation and oxidative stress in metabolic diseases and the micro- and Macro-nutrients intake and the inflammatory response.

Education and Training:

  • PhD, State University of New York at Buffalo (2004)
  • BS, University of Jordan

Employment:

  • UB-IRB Committee member, University at Buffalo (2018-present)
  • Research Director, Medicine, Division of Endocrinology, Diabetes and Metabolism (2005-present)
  • Research Associate Professor, Endocrinology, State University of New York at Buffalo Jacobs School of Medicine & Biomedical Sciences (2014-present)

Awards and Honors:

  • Internal Medicine Training Program Teaching appreciation award (2013)
  • The Pharmacia Corporation International Award for Excellence in Published Clinical Research (2001)

Research Expertise:

  • Mechanisms of insulin resistance: Research focused on understanding role of inflammation and oxidative stress in developing insulin resistance
  • Weight loss quality and quantity: As weight loss drugs are commonly used now, our lab is focused on investigating mechanisms of preserving lean mass we patients are losing weight. We are also interested in understanding best practices for weight loss maintenance.

Research Centers:

  • Clinical and Translational Research Center (CTRC)
  • Diabetes-Endocrinology Center of Western New York

UB 2020 Strategic Strengths:

  • Health and Wellness Across the Lifespan
  • Molecular Recognition in Biological Systems and Bioinformatics

Grants and Sponsored Research:

  • January 2018–December 2025
    An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes
    AstraZeneca Pharmaceuticals LP
    Role: Co-Investigator
    $735,000
  • January 2019–December 2024
    Triple therapy for T1DM with insulin, semaglutide and dapagliflozin
    JDRF
    Role: Co-Principal Investigator
    $1,641,000
  • September 2022–June 2024
    3- Phase 3, Multicenter, Randomized, Parallel-Design, Open Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes treated with Multiple Daily Injection Therapy
    Lilly
    Role: Co-Investigator
    $258,000
  • September 2022–April 2024
    2- A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Display Injections
    Lilly
    Role: Co-Investigator
    $283,500
  • December 2021–December 2022
    Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment
    CTSI
    Role: Principal Investigator
    $50,000
  • July 2021–July 2022
    LIGHT-UP Study service contract
    Gelesis Inc
    Role: Contributor
    $371,000
  • December 2012–November 2019
    Effects of liraglutide treatment in overweight or obese patients with type 1 diabetes
    JDRF
    Role: Co-Investigator
    $600,000
  • August 2012–July 2017
    Liraglutide as an Additional treatment in Type 1 diabetes
    NIH/NIDDK
    Role: Co-Investigator
    $1,580,000
  • May 2025
    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants with Type 1 Diabetes and Obesity or Overweigh
    Lilly USA LLC
    Role: Co-Investigator
    $343,200
  • May 2025
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction Associated STEATOHEPATITIS (MASH)
    Akero Therapeutics Incorporated
    Role: Contributor
    $252,000
  • May 2024
    A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes, Moderate or Severe Renal Impairment with Inadequate Glycemic Control on Basal Insulin with or without Metformin and/or SGLT2 inhibitor (TRANSCEND-T2D-3)
    Lilly
    Role: Co-Investigator
    $315,000
  • May 2024
    1- Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism
    AbbVie
    Role: Co-Investigator
    $340,200
  • January 2023
    3- NATiV3: A randomized, double blind, placebo-controled, multicentre, Phase 3 study evaluating long term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis.
    Inventiva
    Role: Contributor
    $245,700
See all (3 more)

Journal Articles:

See all (100 more)

Abstracts:

  • Husam Ghanim, Ajay Chaudhuri, Jeanne Hejna, Paresh Dandona. (2024) Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment. Journal of the Endocrine Society, Annual Meeting of the Endocrine Society – ENDO 2024. Boston, MassachusettsUnited States (Jun), (12608) Poster
  • Archit Gupta, Mahmoud Nasdar, Husam Ghanim. (2024) Risk of Retinopathy in Patients with Type 2 Diabetes on Semaglutide. Journal of the Endocrine Society., ENDO 2024. Boston, MassachusettsUnited States (Jun), (12338) Poster
  • William Jenkins, Mahmoud Nassar, Husam A. Ghanim. (2024) Gastroparesis Incidence Post-Initiation of Semaglutide Versus Sitagliptin in Type 2 Diabetes: A Retrospective TriNetX Database Analysis. AACE 2024 Annual Meeting. New Orleans, LouisianaUnited States (May) Poster

Professional Memberships:

  • The Obesity Society; Member (2019–present)
  • American Diabetes Association; Professional Membership
  • Endocrine Society; Member

Presentations:

  • "New Advancements in Weight Managment" CME/ Catholic Health Ground Rounds (2024)
  • "Weight Loss Interventions: Quality vs. Quantity" GLSDE 2024 Annual Meeting: Pioneering Endocrine Frontiers: Advanced Practice and Innovative Research (2024)
  • "Weight Loss Interventions: The Past and the Future" DOM City Wide Grand Rounds (2024)
  • "How much can people with type 1 diabetes benefit from adjunct therapies?" 58th Annual European Association for the Study of Diabetes (2022)
  • "Weight loss and body composition: Relevance to Weight Regain" Virtual CME Saturday (2022)
  • "Weight Loss in Older Obese Patients: The Obesity Paradox" Grand Round (2022)

Service Activities:

  • UB Resident & Fellow Research Day; Abstract and poster Judge (2025)
  • 27th Annual UB Resident & Fellow Research Day; Facilitator/Poster Judge (2025)
  • Health Sciences Scholarly Project: As a mentor to UB medical student, I designed and funded a research project for the student to complete before medical school graduation. Student name: Gianna Minnuto; Mentor: Health Sciences Scholarly Project (2025–2027)
  • Medical Student Annual Research Forum; Poster/Abstract Judge (2025)
  • Medical Student Annual Research Forum; Poster/Abstract Judge (2025)
  • 14th Annual Postdoc Symposium; Postdoc Poster Session Judge (2024)
  • 14th Annual Postdoc Symposium; Postdoc Poster Session Judge (2024)
  • Strategic Grant reviewer for Breakthrough T1D; Grant Reviewer (2024–present)
  • Endocrine Research; Assocaite Editor (2024–present)
  • 26th Annual UB Resident & Fellow Research Day; Facilitator/poster judge (2024)
  • Awards of Excellence for Promoting Inclusion and Cultural Diversity.; Reviewer (2024)
  • Medical Students Annual Reseach Forum. Review, judge and rank posters of medical students; Reviewer and Judge (2024)
  • Peace Center of WNY; Volunteer (2023–present)
  • FY24 Training Awards Review, Breakthrough T1D; Reviewer (2023)
  • Review, interview and rank applicants for fellowship position every year; reviewer (2023)
  • Reivew applicant's CV's and patriciate in interviews and ranking; Chief of Nephrology search committee (2023–2024)
  • JDRF FY22 Beta Improving Lives Training AWARD; REVIEWER (2021)
  • Reviewer for Journal of Cellular and Molecular Medicine; Reviewer (2021–present)
  • CTSI Translational Pilot Studies Program; Reviewer (2020)
  • Reviewer for Diabetes, Obesity and Metabolism; Reviewer (2020–present)
  • Discussion group to improve IRB function. Chair: Dr Sanjay Sethi; IRB working group (2019)
  • DOM Research Day abstract reviewer and poster Judge. Research performed by residents, fellows and junior faculty; Abstract Reviewer (2019–present)
  • Reviewer for The Journal of Clinical Endocrinology & Metabolism; Reviewer (2019–present)
  • Islamic Society of Niagara Frontier Sunday School Board president; Sunday School Board president (2018–present)
  • I have been a member of the review committee in UBIRB since 2018. Received excellent evaluation for my role and re-appointed for 3 more years till 2027; IRB review board member (2018–present)
  • Research Staff and volunteer's supervisor. Signing time sheets, assign duties and allocating effort; Research Staff and volunteer's supervisor (2006–present)
  • Provide general and specific research guidance for resident and fellows in the department and division; Endocrine Division Research Director (2005–present)
  • Member of Network of Religious Communities. Supporting peace and understanding in the WNY area; Community Representative

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

875 Ellicott Street
Buffalo, New York 14203
Phone: 716-881-8924
Fax: 716-639-1200
ghanim@buffalo.edu